Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores

K E Broekman,M van Kruchten,H van Tinteren,C Sessa, M Jalving,A K L Reyners

ESMO Open（2021）

引用 4|浏览0

暂无评分

摘要

•Benefit of systemic treatments for recurrent ovarian cancer was scored on the ESMO-MCBS.•From 1127 identified papers, only 3 trials out of 19 that were suitable for grading showed substantial clinical benefit.•Trials demonstrating overall survival benefit are sparse.

查看译文

关键词

clinical benefit,ovarian cancer,ESMO-MCBS,chemotherapy,targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要